Dilon Technologies offers a

large portfolio of
medical technology

to anticipate and fulfill the needs of
the healthcare industry worldwide.

+
Years in medical devices
+
Millions of Lives Improved
+
Countries Worldwide

About Dilon
Technologies® Inc.

Dilon Technologies® Inc., a medical device manufacturer based in Newport News, Virginia, strives to improve the quality of care by providing a wide range of innovative medical device technology that benefits patients around the world. Dilon has a strong medical device portfolio which includes HEMOBLAST Bellows, the only combination powdered surgical hemostat that contains collagen, thrombin and chondroitin sulfate, MarginProbe, a groundbreaking technology for accurate margin assessment in breast cancer surgery, the Navigator System, a surgical gamma probe system for radio-guided lymphatic mapping and tumor localization, TrueView Pro 100, a specimen radiography system (SRS) that uses advanced radiography and automated software to precisely identify tumor lesions in resected or biopsied breast tissue, and the CoPilot, an innovative, portable, and easy to use video laryngoscope.

Learn more

TrueView 100 Pro

Advanced radiography and automated software that precisely identify tumor lesions in resected or biopsied breast tissue.

truview-100-home

MarginProbe®

What if your cancer was removed in just one surgery?

With MarginProbe, surgeons can assess the tissue in the operating room to give them confidence in their assessment of cancerous margins primary lumpectomy surgery.

marginprobe

Navigator System

Freedom with Navigator Drapeless Gamma Probe allows for low-temp sterilization which is in-line with CDC Guidelines and Joint Commission Standards for Disinfection and Sterilization in Healthcare Facilities.

ns

CoPilot VL+

CoPilot VL+ is a portable, affordable, and easy to use, state of the art video laryngoscope system. Video laryngoscopy shouldn’t be a backup plan; it should be the standard of care for all intubation patients.

IMG_9577

Featured News

Next Generation MarginProbeTM

Dilon Technologies Announces Beginning Enrollment in its Pivotal Trial of the Next Generation MarginProbeTM 2 Used in…

Publication of Data Demonstrating

Dilon Technologies Announces the Publication of Data Demonstrating Cost-Savings Results from the Use of MarginProbeTM Compared to…

IMPACT Lourdes awards grant

IMPACT Lourdes members voted to award $30,000 to

More News
How can we help?

Before you commit to a particular
course of treatment, talk to us.